Simplification of the antidiabetic treatment have been recently shown with the SGLT-2 inhibitor canagliflozin in patients with HF and T2D, with significant reduction in number of glucose-lowering drugs, basal insulin dose, and percentage of patients who used basal insulin after switching non-insulin glucose lowering drugs (excluding metformin) to canagliflozin (48). This evidence concerns the gene SLC5A2 and hydrops fetalis.